Company Profile
Quoin Stock Price, News & Catalysts
- Ticker:
- QNRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.19 USD (+1.96%)
Close
Last updated: August 17, 2026
9.16M USD
Market cap
Why the stock is moving
Following the latest company update, âQuoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsâ, QNRX closed down 15.9% at $5.09 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Rare Dermatology Company
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration.
QRX003 in Netherton Syndrome
QRX003, also referred to as QYLEKI, is the company's lead topical program for Netherton syndrome. It has received orphan-drug designation in the United States, European Union, and Japan, as well as FDA Fast Track and Rare Pediatric Disease designations.
Peeling Skin Syndrome Expansion
Quoin is expanding QRX003 into peeling skin syndrome, another rare inherited skin disorder. The FDA has cleared the investigational new drug application for this indication, allowing the company to advance a company-sponsored study in the United States and Europe.
QRX009 Rapamycin Platform
QRX009 is a topical rapamycin formulation platform being explored in rare dermatologic conditions including pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex. Quoin plans to use investigator-sponsored work and additional regulatory filings to broaden the platform's clinical reach.
Future catalysts
- Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
- Submission of an additional IND for the QRX009 platform by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Quoin (QNRX)?
Quoin (QNRX) most recently closed at 5.19 USD, a +1.96% move versus the previous session.
What is the market cap of Quoin (QNRX)?
Quoin currently has a market capitalization of 9.16M USD on BioPharmSignal.
What does Quoin do?
Rare Dermatology Company Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration. QRX003 in Netherton Syndrome QRX003, also...
On which exchange is QNRX stock listed?
Quoin (QNRX) is associated with NASDAQ, United States, Biopharma.
What is Rare?
Rare Dermatology Company Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases.
Which conditions is Quoin targeting with Rare?
Quoin is associated with dermatology based on its company overview and current catalyst commentary.
How does Quoin describe recent progress with Rare?
Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026. Submission of an additional IND for the QRX009 platform by year-end 2026.
What is Dermatology?
Rare Dermatology Company Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases.